InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - ETF Exposure

Current share price for NEU : $20.600 0.64 (3.21%)+

Neuren Pharmaceuticals Limited (NEU) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a biopharmaceutical company developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted orphan drug designation in the United States.

NEU General Information +

ASX Code NEU
Website http://www.neurenpharma.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 2,611
NEU Share Price $20.600
Day High $20.640
Day Low $19.990
Last Close $19.960
NEU Share Price Movement $0.64 ( 3.21% )
Prices as at 15:36, 3 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to NEU

As a significant Australian company by market capitalisation, NEU is held across 25 ETFs spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when NEU moves, funds like SMLL, IMPQ, AQLT, SSO and ISO that hold it can move with it.

For more concentrated exposure, ETFs such as SMLL (BetaShares Australian Small Companies Select Fund (Managed Fund)) allocate about 2% to NEU , while the average exposure across all 25 ETFs that hold it is around 0.4% .

Top ETF holdings

Last updated: ETF data and holdings as at 2 September 2026

Own NEU directly or through an ETF?

How does holding Neuren Pharmaceuticals Limited (NEU) shares directly compare to ETFs that include it?

NEU Direct
SMLL
ASX 		IMPQ
ASX 		AQLT
ASX 		SSO
ASX 		ISO
ASX
Holdings 1 company 59 holdings 41 holdings 46 holdings 202 holdings 201 holdings
NEU Weight 100% 2% 1.7% 1.4% 0.9% 0.9%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.39% p.a. 0.89% p.a. 0.35% p.a. 0.5% p.a. 0.55% p.a.
Approx. Yield - 2.89% 2.18% 4.08% 9.13% 4.26%
Star Ratings - starstarstarstar star starstarstarstar starstar starstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not NEU's direct yield. Annual cost uses each ETF's MER.

NEU Exposure on $10,000 investment

How a $10,000 investment in Neuren Pharmaceuticals Limited (NEU) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Neuren Pharmaceuticals Limited (NEU) Direct share $20.600 2.23% +$223 $10,223
BetaShares Australian Small Companies Select Fund (Managed Fund) (SMLL) Equity - Australia Strategy $4.540 -1.09% -$109 $9,891
eInvest Better Future (Managed Fund) (IMPQ) Equity - Australia Small/Mid Cap $4.130 -2.59% -$259 $9,741
BetaShares Australian Quality ETF (AQLT) Equity - Australia Strategy $35.280 -2.51% -$251 $9,749
SPDR S&P/ASX Small Ordinaries Fund (SSO) Equity - Australia Small/Mid Cap $14.690 -3.86% -$386 $9,614
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) Equity - Australia Small/Mid Cap $5.130 -3.57% -$357 $9,643

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Neuren Pharmaceuticals Limited (NEU) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 15¢ 100% 15 Sep 2026 7 Oct 2026 - - -

See all dividends from Neuren Pharmaceuticals Limited (NEU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Neuren Pharmaceuticals Limited (NEU) price-sensitive announcements

NEU - Growing royalty anchors Neuren first ever dividend program
Neuren Pharmaceuticals Limited announced its first-ever dividend program, anchored by incr
Neuren Pharmaceuticals Limited (NEU)
26 Aug 2026 | 9:47 AM
NEU - Half Yearly Report and Accounts
For the half-year ending June 30, 2026, Neuren Pharmaceuticals Limited reported a profit o
Neuren Pharmaceuticals Limited (NEU)
26 Aug 2026 | 9:25 AM
NEU - European Commission grants marketing authorisation for DAYBU
Neuren Pharmaceuticals Limited announced that the European Commission has granted marketin
Neuren Pharmaceuticals Limited (NEU)
25 Aug 2026 | 8:31 AM
NEU - Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
Neuren Pharmaceuticals Limited reported a record Q2 2026 DAYBUE net sales of US$125 millio
Neuren Pharmaceuticals Limited (NEU)
5 Aug 2026 | 9:52 AM

Neuren Pharmaceuticals Limited (NEU) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $2,612 Corporate Presentation, 2 September 2026 2 Sep 2026 8:50AM $19.890 $20.600 risen by 3.57%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $2,612 Dividend/Distribution - NEU 26 Aug 2026 4:56PM $20.150 $20.600 risen by 2.23%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $2,612 Investor presentation, 26 August 2026 26 Aug 2026 10:40AM $22.370 $20.600 fallen by 7.91%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $2,612 Growing royalty anchors Neuren first ever dividend program 26 Aug 2026 9:47AM $22.530 $20.600 fallen by 8.57%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $2,612 Half Yearly Report and Accounts 26 Aug 2026 9:25AM $22.530 $20.600 fallen by 8.57%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $2,612 European Commission grants marketing authorisation for DAYBU 25 Aug 2026 8:31AM $22.450 $20.600 fallen by 8.24%

NEU Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 $57.00 96.60% 35.00 39.00 2.00% 0.0%
2026F C2 $29.00 24.60% 68.80 33.00 1.70% 0.0%
2025A $30.44 $23.30 -78.60% 67.30 0.00 0.00% 0.0%

NEU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
Clarity Pharmaceuticals Ltd (CU6) $869M 0.4454 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,522M -0.7857 0.2462 0.9655 85.4749 68.5862 34.8947 0.00% 1.66% 1.96%

NEU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 2.51 73.60 7.47 1.30
Market 0.38 13.40 1.16 0.81
Sector 0.65 32.10 2.38 2.59

NEU Directors

Name Position Start Date
Mr Jonathan (Jon) Charles Pilcher Chief Executive Officer, Managing Director 14 Jun 2021
Ms Dianne Margaret Angus Non-Executive Director 1 Jul 2018
Dr Jenny Lee Harry Non-Executive Director 7 Jul 2018
Mr Joseph(Joe) Basile Non-Executive Director 2 Mar 2023
Mr Patrick Davies Non-Executive Director, Non-Executive Chairman 1 Jul 2018

Neuren Pharmaceuticals Limited (NEU) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
5 Mar 2026 BASILE, Joseph(Joe) Buy Direct Shares 12,300 $12.340 $151,782.000
8 Sep 2025 PILCHER, Jonathan (Jon) Sell Indirect Shares 398,207 $20.000 $7,964,140.000
22 Jul 2025 PILCHER, Jonathan (Jon) Buy Direct Shares 1,500,000 $1.840 $2,760,000.000

See all changes in directors' interest & trades for Neuren Pharmaceuticals Limited (NEU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NEU Management

Name Position
Gerry Zhao Chief Business Officer
Lauren Frazer Chief Financial Officer,Company Secretary
Liza Squires Chief Medical Officer
Clive Blower Chief Operations Officer
Daryl Dekarske Chief Regulatory Officer
Larry Glass Chief Science Officer

NEU Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neuren Pharmaceuticals Limited (NEU). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
6,492,295 (5.02%) Vanguard Group
6,412,618 (5.01%) State Street Corporation and subsidiaries

NEU Calendar of Events

Date Event
25 August 2027 Report (Interim)
23 April 2027 Report (Annual)
26 February 2027 Report (Prelim)
07 October 2026 Div Pay Date
16 September 2026 Books Close
15 September 2026 Div Ex Date

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.